Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)

  • End date
    Mar 1, 2024
  • participants needed
  • sponsor
    University Hospital Heidelberg
Updated on 4 May 2021


The study is a randomized phase III trial with a 2x2 factorial design with measurable residual disease and event-free survival as primary endpoints, respectively. Patients are upfront randomized for the two induction schedules (Gemtuzumab Ozogamicin (GO)-147 versus GO-1; ratio 1:1) and for Glasdegib or Placebo (double blinded, ratio 1:1) as adjunct to consolidation therapy and as single agent 6 months maintenance therapy. Chemotherapy backbone for induction therapy is standard 7+3 with cytarabine 200mg/m continuously day 1 to day 7, daunorubicin 60mg/m days 1, 2 and 3 and for consolidation therapy intermediate dose cytarabine (1g/m, bi-daily, days 1,2,3). The trial is designed to gain evidence of anti-leukemic activity of GO and Glasdegib in older patients with newly diagnosed acute myeloid leukemia.

Condition Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), acute myelogenous leukemia, anll, acute myeloblastic leukemia
Treatment Placebo Oral Tablet, Glasdegib, Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1
Clinical Study IdentifierNCT04093505
SponsorUniversity Hospital Heidelberg
Last Modified on4 May 2021


Yes No Not Sure

Inclusion Criteria

Patients with newly diagnosed acute myeloid leukemia according to the 2016 WHO classification
Genetic and immunophenotypic assessment in one of the central laboratories
No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis ( 7 days)
Age 60 years, no upper age limit
ECOG performance status (ECOG PS) 2. See appendix 18.1
Pregnancy and childbearing potential
Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)
Female patients of reproductive age must agree to avoid getting pregnant while on therapy
WOCBP must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy) during study and 6 months after end of study/treatment. Hormonal contraception is an inadequate method of birth control
Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child during study and 6 months after end of study/treatment
Signed written informed consent
Ability of patient to understand character and consequences of the clinical trial

Exclusion Criteria

Patients with known active central nervous system leukemia (assessed clinically)
Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent for AML. (Treatment of a preceding MDS (myelodysplastic syndrome) with HMA is not an exclusion criterion.)
Inadequate renal function: creatinine > 1.5 x upper normal serum level; estimated creatinine clearance 30 ml/min (calculated using the standard method for the institution)
Inadequate liver function: ALT and AST 2.5 x ULN), total bilirubin 1.5 x ULN; Alkaline phosphatase 2.5 x ULN. Known liver cirrhosis or history of veno-occlusive disease (VOD) or history of Sinusoidal Obstruction Syndrome (SOS)
Uncontrolled hypertension; severe obstructive or restrictive ventilation disorder
Any one of the following ongoing or in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, arrhythmias (including sustained ventricular tachyarrhythmia), right or left bundle branch block and bifascicular block, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF NYHA III/IV), cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism; as well as bradycardia defined as <50 bpms
QTc interval >470 msec using the Fredericia correction (QTcF)
Uncontrolled infection
Patients known to be refractory to platelet or packed red cell transfusions as per institutional guidelines, or who are known to refuse or who are likely to refuse blood product support
Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy for more than one year and are considered by their physician to be at less than 30% risk of relapse within one year
Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
Known or suspected active alcohol or drug abuse
Known positivity for HIV, active HBV, HCV, or hepatitis A infection
Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy
No consent for biobanking and for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician about study participation
Pregnancy and lactation
History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
Participation in a clinical study involving an investigational drug(s) (Phases 1-4) within 4 weeks prior to study entry
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note